GS-441524 prodrug
- Generic Name
- GS-441524 prodrug
Study of Obeldesivir to Treat Children With Respiratory Syncytial Virus (RSV) Infection
- First Posted Date
- 2025-01-20
- Last Posted Date
- 2025-05-15
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 130
- Registration Number
- NCT06784973
- Locations
- π―π΅
Uchida child clinic, Fukuoka, Japan
π―π΅Shindo Children's Clinic, Fukuoka, Japan
π―π΅SEKI Children's CLINIC, Fukuoka, Japan
Study of Obeldesivir as Postexposure Prophylaxis for Marburg Virus Disease
- Conditions
- Postexposure Prophylaxis Marburg Virus Disease
- Interventions
- First Posted Date
- 2024-11-12
- Last Posted Date
- 2025-05-06
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 400
- Registration Number
- NCT06682234
Study of Obeldesivir to Treat Nonhospitalized Adults With Acute Respiratory Syncytial Virus (RSV) Infection
- First Posted Date
- 2024-09-05
- Last Posted Date
- 2025-03-24
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 240
- Registration Number
- NCT06585150
- Locations
- πΊπΈ
Central Alabama Research, Birmingham, Alabama, United States
πΊπΈCullman Clinical Trials, Cullman, Alabama, United States
πΊπΈLakeview Clinical Research, LLC, Guntersville, Alabama, United States
Study of Obeldesivir in Children and Adolescents With COVID-19
- First Posted Date
- 2023-08-18
- Last Posted Date
- 2025-02-03
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 3
- Registration Number
- NCT05996744
- Locations
- πΊπΈ
UF Health- Shands Hospital, Gainesville, Florida, United States
πΊπΈStanford University Medical Center, Palo Alto, California, United States
πΊπΈTrinity Clinical Research, LLC, Centreville, Alabama, United States
Study of Obeldesivir in Nonhospitalized Participants With COVID-19
- First Posted Date
- 2023-02-08
- Last Posted Date
- 2024-12-24
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 2011
- Registration Number
- NCT05715528
- Locations
- πΊπΈ
Innovative Health, Hollywood, Florida, United States
πΊπΈPalm Springs Community Health Center, Miami Lakes, Florida, United States
πΊπΈInstitute for Liver Health dba Arizona Clinical Trials, Chandler, Arizona, United States
Study of Obeldesivir in Participants With COVID-19 Who Have a High Risk of Developing Serious or Severe Illness
- First Posted Date
- 2022-11-02
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 468
- Registration Number
- NCT05603143
- Locations
- π΅πΉ
Hospital CUF Descobertas, Lisboa, Portugal
π¨π³China Medical University Hospital, Taichung, Taiwan
π§π¬Diagnostic and Consulting Center Aleksandrovska EOOD, Sofia, Bulgaria
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.